Lv1
50 积分 2026-07-20 加入
Pathological Response to Neoadjuvant Tislelizumab (TIS) Plus Platinum-Doublet (PtDb) Chemotherapy (CT) in Resectable Stage II-IIIA NSCLC Patients (pts) in the Phase 3 (Ph3) RATIONALE-315 Trial
1天前
已关闭
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
1天前
已完结
ctDNA dynamics and neoadjuvant treatment responses in patients with resectable NSCLC from the phase 3 AEGEAN trial
1天前
已关闭
OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial
1天前
已完结
皖公网安备34019202002308
